Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2000
08/03/2000WO2000044733A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
08/03/2000WO2000044731A1 Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
08/03/2000WO2000044730A1 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000WO2000044716A1 Acetylenic sulfonamide thiol tace inhibitors
08/03/2000WO2000044714A1 S-nitrosothiols as agents for the treatment of circulatory dysfunctions
08/03/2000WO2000044713A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
08/03/2000WO2000044711A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044710A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044709A2 ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044707A1 Novel substituted guanidine derivatives and process for the preparation thereof
08/03/2000WO2000044384A1 USE OF PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS
08/03/2000WO2000044378A1 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
08/03/2000WO2000044375A1 Antioxidant compositions and methods for companion animals
08/03/2000WO2000044371A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000WO2000044370A1 Drugs, foods and oral compositions containing stilbene-type compounds
08/03/2000WO2000044365A1 Methods for preventing graft rejection and ischemia-reperfusion injury
08/03/2000WO2000044362A2 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
08/03/2000WO2000044361A2 Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders
08/03/2000WO2000044357A2 Agent for preventing in-stent restenoses and post-operative inflammations
08/03/2000WO2000044355A1 Moxonidine salts
08/03/2000WO2000044354A1 Lyophilisates with improved reconstitutibility
08/03/2000WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000WO2000044306A1 Biodegradable polymeriprotein based coils for intralumenal implants
08/03/2000WO2000037062A3 Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
08/03/2000WO2000027850A3 Crf receptor antagonists and methods relating thereto
08/03/2000WO2000023407A3 Ureido-thiobutyric acid derivatives as ppar-agonists
08/03/2000WO2000013701A3 Angiogenically effective unit dose of fgf-2 and method of use
08/03/2000WO2000009675A9 Adenovirus formulations for gene therapy
08/03/2000WO2000006589A9 Prostate derived ets factor
08/03/2000WO2000006185A3 Methods of using lanreotide, a somatostatin analogue
08/03/2000DE19903385A1 Mittel zur Prävention von In-Stent Restenosen und postoperativen Entzündungen Agents for the prevention of in-stent restenosis and postoperative inflammation
08/03/2000DE19903275A1 Lyophilisate mit verbesserter Rekonstituierbarkeit Lyophilisates with improved reconstitutability
08/03/2000DE19903095A1 Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium Production of gamma-linolenic acid from protozoa of the genus Colpidium
08/03/2000DE19901921A1 Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels Polymorphs of telmisartan, to processes for their preparation and their use for the preparation of a medicament
08/03/2000DE10003771A1 Treating cardiac infarction-induced damage to myocardium, using moxonidine to restore or rehabilitate myocardial state after infarction
08/03/2000CA2361614E Compositions for treating inflammatory response
08/03/2000CA2361518A1 Purine inhibitors of cyclin dependent kinase 2 and ikb-.alpha.
08/03/2000CA2361479A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
08/03/2000CA2360997A1 Non-invasive method for detecting target rna
08/03/2000CA2360691A1 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
08/03/2000CA2360674A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000CA2360672A1 Methods for preventing graft rejection and ischemia-reperfusion injury
08/03/2000CA2360643A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000CA2359317A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000CA2359034A1 Pyrazino(aza)indole derivatives
08/03/2000CA2359011A1 Thiazolopyrimidine compound, its production and use
08/03/2000CA2358967A1 Hesperitin pro-forms with enhanced bioavailability
08/03/2000CA2358964A1 Carbamate derivatives of diaryl 1,3,4-oxadiazolone
08/03/2000CA2356855A1 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356481A1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356480A1 Acetylenic sulfonamide thiol tace inhibitors
08/03/2000CA2356346A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
08/03/2000CA2356345A1 Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356313A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
08/03/2000CA2356299A1 Acetylenic .alpha.-amino acid-based sulfonamide hydroxamic acid tace inhibitors
08/03/2000CA2356267A1 2,3,4,5-tetrahydro-1h-¬1,4|benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/02/2000EP1024199A2 Recovery of gamma-linolenic acid from protozoa of the genus Colpidium
08/02/2000EP1023905A2 Pharmaceutical composition containing S-nitroso-immunoglobulins and use thereof
08/02/2000EP1023900A2 Pharmaceutical composition containing S-nitroso-lipoproteins and use thereof
08/02/2000EP1023445A1 Cadherin derived growth factor and the application thereof
08/02/2000EP1023441A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function
08/02/2000EP1023324A1 Trivalent thrombin inhibitor
08/02/2000EP1023322A1 Novel npy family member
08/02/2000EP1023318A1 Dipeptides for the treatment of diseases related to the biological effect of endothelin
08/02/2000EP1023295A1 Fibrinogen receptor antagonist prodrugs
08/02/2000EP1023287A1 3-oxo-2(h)-1,2,4-triazine derivatives as ligands of 5ht1a receptors
08/02/2000EP1023282A1 Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors
08/02/2000EP1023277A1 Novel 3,4-diarylthiazolin-2-one or -2-thione derivatives, preparation methods and uses in therapy
08/02/2000EP1023273A1 Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5t h1a receptors
08/02/2000EP1023267A1 Pyridyl compounds and pharmaceutical compositions containing them
08/02/2000EP1023263A1 Novel vitamin d analogues
08/02/2000EP1023081A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
08/02/2000EP1023080A1 Ligand binding site of rage and uses thereof
08/02/2000EP1023073A1 Vitronectin receptor antagonist
08/02/2000EP1023067A2 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
08/02/2000EP1023066A1 Novel pyrazole and pyrazoline substituted compounds
08/02/2000EP1023063A1 INDENO 1,2-c]-, NAPHTHO 1,2-c]- AND BENZO 6,7]CYCLOHEPTA 1,2-c]PYRAZOLE DERIVATIVES
08/02/2000EP1023061A1 Somatostatin agonists
08/02/2000EP1023060A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
08/02/2000EP1023059A2 Pharmaceutical preparations
08/02/2000EP1022945A2 Method and formulation for treating vascular disease
08/02/2000CN1261895A Cyclic azapeptide with angiogenic effect
08/02/2000CN1261877A 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
08/02/2000CN1261803A Antioxidant enhancement of therapy for hyperproliferative conditions
08/02/2000CN1261795A Compounds and methods
08/02/2000CN1261534A Medicinal composition containing naphthyl compound
08/02/2000CN1055089C Intermediate of protein kinase C inhibitor and its preparation
08/02/2000CN1054995C Chinese medicine for treatment of angiitis
08/02/2000CN1054984C Medicine for treating heart diseases
08/01/2000US6096902 Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
08/01/2000US6096897 Endothelin receptor antagonists
08/01/2000US6096840 Gas phase polymerization process
08/01/2000US6096777 Method for inhibiting the expression of Fas
08/01/2000US6096774 Energetic nitramine-linked azoles and hydroxylammonium salts as oxidizers, intiators and gas generators
08/01/2000US6096773 Inhibitor of binding of integrin to its receptors, such as (vascular cell adhesion molecule-1) and fibronectin and useful for controlling the diseases induced by binding
08/01/2000US6096766 Useful in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia
08/01/2000US6096753 Substituted pyrimidinone and pyridone compounds and methods of use
08/01/2000US6096748 Pyrimidine compounds useful in treating cytokine mediated diseases
08/01/2000US6096739 Treatment for CNS injuries
08/01/2000US6096735 Benzoheterocyclic derivatives
1 ... 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 ... 1595